Anal Cancer Archives - Cancer Therapy Advisor

A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.

This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.

ASCO GI 2020

Phase 2 Results: Pembrolizumab Shows Antitumor Activity and a Manageable Safety Profile in Anal Squamous Cell Carcinoma

By

Susan Moench, PhD, PA-C

January 24, 2020

This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.

Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.

Skin Cancer

Incidence of Squamous Cell Carcinoma of the Anus Increasing

November 21, 2019

Greater increase seen for distant-stage and regional-stage SCCA than for localized-stage SSCA.

Prognosis is Poorer in Patients with Lung Cancer Who Are HIV-Infected

Gastrointestinal Cancers

Rates of Anal Cancer Precursors High in Women Living With HIV

July 23, 2019

Authors call for new screening strategies for anal cancer prevention in women living with HIV.

Clinical trial data regarding deep molecular response outcomes suggest that dasatinib and nilotinib

Gastrointestinal Cancer Clinical Trials

High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer

By

Susan Moench, PhD, PA-C

February 19, 2019

High tumor expression of IDO1 may identify whether a patient is likely to respond to immunotherapy, according to study authors.

Increased insurance and clinical trial access, plus diversification of the medical workforce, may he

Gastrointestinal Cancers

Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients

By

James Nam, PharmD

September 22, 2017

Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.

Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazop

Head and Neck Cancer

Phase 1b/2 Study of DPX-E7 + Cyclophosphamide in HPV-positive Cancers

By

Cancer Therapy Advisor Staff

April 11, 2017

Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.

Gastrointestinal Cancers

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

By

Jason Hoffman, PharmD, RPh

February 21, 2017

Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).